# Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight Loss

> **NCT07446998** · PHASE2 · RECRUITING · sponsor: **Veru Inc.** · enrollment: 200 (estimated)

## Conditions studied

- Obesity & Overweight
- Mobility Disability
- HOMA-IR

## Interventions

- **DRUG:** Enobosarm
- **DRUG:** Semaglutide (Wegovy) weekly injection

## Key facts

- **NCT ID:** NCT07446998
- **Lead sponsor:** Veru Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-26
- **Primary completion:** 2027-10
- **Final completion:** 2027-12
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2026-04-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07446998

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07446998, "Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight Loss". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07446998. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*